Special Issue

Bioactivity of Transition Metal-Based Complexes

Message from the Guest Editors

The application of transition metal complexes in chemotherapy is well established. Cisplatin is the first cytostatic drug based on a metal ion used in the treatment of various types of cancers. However, serious side effects and drug resistance can occur during its clinical application. Thus, huge efforts are being made in the development of metal-based complexes in order to design the compound with a superior pharmacological response, as compared to cisplatin. In recent years, numerous complexes of platinum, palladium, ruthenium, gold, rhodium, osmium, iridium, zinc, copper, and other transition metals with significant antitumor activity against various carcinogenic cells in vitro and in vivo have been synthesized. In this Special Issue, we wish to address the most recent advances in the field of transition metal-based complexes and their potential clinical use by hosting a mix of original research articles and short critical reviews.

Guest Editors

Dr. Snežana Jovanović-Stević

Dr. Tanja Soldatović

Dr. Ralph Puchta

Deadline for manuscript submissions

closed (31 August 2023)



Inorganics

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1



mdpi.com/si/117617

Inorganics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
inorganics@mdpi.com

mdpi.com/journal/inorganics





Inorganics

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1



About the Journal

Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals.

Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and Inorganics offers authors the opportunity to publish exciting new research in an open access format.

Editor-in-Chief

Prof. Dr. Duncan H. Gregory

School of Chemistry, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Inorganic and Nuclear) / CiteScore - Q2 (Inorganic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

